Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Cyclosporine Inhalation Solution (CIS) in Lung Transplant Recipients

Study:

An Open-label Treatment Use Protocol of Cyclosporine Inhalation Solution (CIS) in Lung Transplant Recipients

Rationale:

n/a

Purpose:

Currently there are no approved therapies for lung transplant recipients in the United States (US). Treatment with CIS following lung transplantation has previously been demonstrated to result in a clinically meaningful improvement in survival and chronic rejection-free survival compared to placebo, but additional data supporting its use is needed prior to Food and Drug Administration (FDA) approval. This treatment use protocol is a mechanism for providing eligible lung transplant recipients early access to CIS in advance of FDA approval.

Study Status: No longer available

Recruiting:
n/a

Condition Intervention Phase
Lung Transplant Drug: Cyclosporine Inhalation Solution N/A

Verified by APT Pharmaceuticals, Inc. September, 2012

Sponsored by: APT Pharmaceuticals, Inc.
Information provided by: APT Pharmaceuticals, Inc.
ClinicalTrials.gov identifier: NCT00633373

Study Type: Interventional

Study Design: N/A

Cleveland Clinic
Cleveland, Ohio 44195
United States

n/a

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site